ATE402192T1 - Anti-ccr4 antikörper und fragmente davon - Google Patents
Anti-ccr4 antikörper und fragmente davonInfo
- Publication number
- ATE402192T1 ATE402192T1 AT01908280T AT01908280T ATE402192T1 AT E402192 T1 ATE402192 T1 AT E402192T1 AT 01908280 T AT01908280 T AT 01908280T AT 01908280 T AT01908280 T AT 01908280T AT E402192 T1 ATE402192 T1 AT E402192T1
- Authority
- AT
- Austria
- Prior art keywords
- ccr4
- antibody fragment
- antibody
- recombinant antibody
- cell
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 abstract 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 abstract 3
- 239000000032 diagnostic agent Substances 0.000 abstract 2
- 229940039227 diagnostic agent Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 102000043444 human CCR4 Human genes 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000059508 | 2000-03-03 | ||
| JP2000401563 | 2000-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402192T1 true ATE402192T1 (de) | 2008-08-15 |
Family
ID=26586785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01908280T ATE402192T1 (de) | 2000-03-03 | 2001-03-02 | Anti-ccr4 antikörper und fragmente davon |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US6989145B2 (de) |
| EP (2) | EP1270595B1 (de) |
| JP (1) | JP3926153B2 (de) |
| KR (1) | KR100890873B1 (de) |
| CN (1) | CN100455599C (de) |
| AT (1) | ATE402192T1 (de) |
| AU (2) | AU2001236073B2 (de) |
| CA (1) | CA2401491C (de) |
| CY (1) | CY1108397T1 (de) |
| DE (1) | DE60134962D1 (de) |
| DK (1) | DK1270595T3 (de) |
| ES (1) | ES2309050T3 (de) |
| PT (1) | PT1270595E (de) |
| SI (1) | SI1270595T1 (de) |
| WO (1) | WO2001064754A1 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU3672800A (en) * | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| MXPA03008001A (es) * | 2001-03-06 | 2004-10-15 | Dow Chemical Co | Celula vegetal que tiene funcion de adicion de cadena de azucar tipo animal. |
| MXPA03009797A (es) * | 2001-04-26 | 2004-01-29 | Biogen Inc | ANTICUERPOS PARA BLOQUEO DE PROTEiNA CRIPTO Y USO DE LOS MISMOS. |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| KR100959248B1 (ko) * | 2001-08-31 | 2010-05-26 | 교와 핫꼬 기린 가부시키가이샤 | 사람형 ｃｄｒ-이식 항체 및 이의 항체 단편 |
| CA2469082A1 (en) * | 2001-12-04 | 2003-06-12 | Raj K. Puri | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| US20050095242A1 (en) * | 2002-02-28 | 2005-05-05 | Ryuzo Ueda | Diagnostics and remedies for interstitial pneumonia |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| WO2004072646A1 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5) |
| CA2529945A1 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| EP1698640B2 (de) | 2003-10-01 | 2019-06-19 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| ES2775204T3 (es) | 2003-12-23 | 2020-07-24 | Genentech Inc | Nuevos anticuerpos anti IL13 y usos de los mismos |
| US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| WO2009001840A1 (ja) * | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| JP5552630B2 (ja) * | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
| GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| AU2011222012C1 (en) | 2010-03-02 | 2015-02-26 | Kyowa Kirin Co., Ltd. | Modified antibody composition |
| GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
| WO2012083132A2 (en) | 2010-12-16 | 2012-06-21 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| EP2723380B1 (de) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Leichtkettige immunglobulin- fusionsproteine und verfahren zu ihrer anwendung |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| BR112015000068A2 (pt) | 2012-07-06 | 2017-08-08 | Kyowa Hakko Kirin Co Ltd | método terapêutico e medicamento para mielopatia associada a htlv-1 (ham) |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| NZ756750A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| JP6795505B2 (ja) | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| AU2016293667A1 (en) | 2015-07-14 | 2018-01-04 | Kyowa Kirin Co., Ltd. | A therapeutic agent for a tumor comprising an IDO inhibitor administered in combination with an antibody |
| EP3393663B1 (de) | 2015-12-22 | 2021-04-14 | 3M Innovative Properties Company | Methode zur partitionierung einer wässrigen probe |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US12053512B2 (en) | 2016-12-08 | 2024-08-06 | Nantbio, Inc. | Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| EP3765069A1 (de) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptid-vakzine gegen interleukin-31 |
| EP3773717A4 (de) * | 2018-03-29 | 2022-05-11 | REMD Biotherapeutics, Inc. | Behandlung von autoimmun- und entzündungserkrankungen mit antikörpern, die interleukin-17a (il-17a) binden |
| CA3119467A1 (en) | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US19341A (en) * | 1858-02-16 | Louis beauche | ||
| US160015A (en) * | 1875-02-23 | Improvement in devices for cutting out sheet-metal washers | ||
| US187930A (en) * | 1877-02-27 | Improvement in processes of preserving meat | ||
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| US5914110A (en) | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| JPH0853355A (ja) | 1994-08-12 | 1996-02-27 | Taisho Pharmaceut Co Ltd | Ｉｌ−５産生抑制剤 |
| GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| PL318594A1 (en) * | 1995-06-07 | 1997-06-23 | Icos Corp | Chemokine and analogues thereof originating from macrophages |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| EP1030662B1 (de) | 1997-11-12 | 2006-08-02 | F. Hoffmann-La Roche Ag | Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten |
| US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
| KR20010083069A (ko) | 1998-06-26 | 2001-08-31 | 나가야마 오사무 | 고칼슘혈증치료제 |
| US6245332B1 (en) * | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
| US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| EP1050307A1 (de) * | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 Antagoniste in Sepsis |
| KR100959248B1 (ko) | 2001-08-31 | 2010-05-26 | 교와 핫꼬 기린 가부시키가이샤 | 사람형 ｃｄｒ-이식 항체 및 이의 항체 단편 |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| DE602004029934D1 (de) * | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
-
2001
- 2001-03-02 AU AU2001236073A patent/AU2001236073B2/en active Active
- 2001-03-02 AT AT01908280T patent/ATE402192T1/de active
- 2001-03-02 CN CNB018059902A patent/CN100455599C/zh not_active Expired - Lifetime
- 2001-03-02 AU AU3607301A patent/AU3607301A/xx active Pending
- 2001-03-02 ES ES01908280T patent/ES2309050T3/es not_active Expired - Lifetime
- 2001-03-02 DK DK01908280T patent/DK1270595T3/da active
- 2001-03-02 PT PT01908280T patent/PT1270595E/pt unknown
- 2001-03-02 EP EP01908280A patent/EP1270595B1/de not_active Expired - Lifetime
- 2001-03-02 SI SI200130859T patent/SI1270595T1/sl unknown
- 2001-03-02 CA CA2401491A patent/CA2401491C/en not_active Expired - Lifetime
- 2001-03-02 EP EP08013028A patent/EP1992644A1/de not_active Withdrawn
- 2001-03-02 KR KR1020027011583A patent/KR100890873B1/ko not_active Expired - Lifetime
- 2001-03-02 WO PCT/JP2001/001656 patent/WO2001064754A1/ja not_active Ceased
- 2001-03-02 US US09/796,744 patent/US6989145B2/en not_active Expired - Lifetime
- 2001-03-02 DE DE60134962T patent/DE60134962D1/de not_active Expired - Lifetime
- 2001-03-02 JP JP2001564247A patent/JP3926153B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-31 US US11/094,718 patent/US7666418B2/en not_active Expired - Fee Related
-
2008
- 2008-10-06 CY CY20081101104T patent/CY1108397T1/el unknown
-
2010
- 2010-01-08 US US12/684,651 patent/US8197814B2/en not_active Expired - Fee Related
-
2012
- 2012-06-08 US US13/492,465 patent/US8632996B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7666418B2 (en) | 2010-02-23 |
| SI1270595T1 (sl) | 2008-12-31 |
| DE60134962D1 (de) | 2008-09-04 |
| WO2001064754A1 (en) | 2001-09-07 |
| AU2001236073B2 (en) | 2006-10-19 |
| US6989145B2 (en) | 2006-01-24 |
| KR20020089377A (ko) | 2002-11-29 |
| EP1270595A4 (de) | 2005-07-27 |
| EP1270595A1 (de) | 2003-01-02 |
| US20050187380A1 (en) | 2005-08-25 |
| US20020098527A1 (en) | 2002-07-25 |
| PT1270595E (pt) | 2008-09-16 |
| CA2401491C (en) | 2011-07-05 |
| CN100455599C (zh) | 2009-01-28 |
| CY1108397T1 (el) | 2014-02-12 |
| KR100890873B1 (ko) | 2009-03-31 |
| US20120276090A1 (en) | 2012-11-01 |
| DK1270595T3 (da) | 2008-11-10 |
| EP1270595B1 (de) | 2008-07-23 |
| AU3607301A (en) | 2001-09-12 |
| CA2401491A1 (en) | 2001-09-07 |
| ES2309050T3 (es) | 2008-12-16 |
| US8632996B2 (en) | 2014-01-21 |
| US8197814B2 (en) | 2012-06-12 |
| US20100221178A1 (en) | 2010-09-02 |
| CN1407993A (zh) | 2003-04-02 |
| JP3926153B2 (ja) | 2007-06-06 |
| EP1992644A1 (de) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE402192T1 (de) | Anti-ccr4 antikörper und fragmente davon | |
| EA200500497A2 (ru) | Антитела к ifn-γ и способ получени я и применения антител | |
| TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
| WO2001064751A3 (en) | High potency recombinant antibodies and method for producing them | |
| MA28418B1 (fr) | Anticorps liant un recepteur de l'interleucine 4 | |
| HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
| MXPA03000103A (es) | Antigenos de streptococcus. | |
| EA200500441A1 (ru) | Терапевтическое человеческое моноклональное антитело против il-1r1 | |
| DK0980429T3 (da) | Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder | |
| PE20030473A1 (es) | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular | |
| IL144265A0 (en) | Use of antibodies for the vaccination against cancer | |
| WO2005120166A3 (en) | Antibodies for selective apoptosis of cells | |
| SE0302312D0 (sv) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| IT1307864B1 (it) | Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di | |
| WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| ATE537257T1 (de) | Mit iga-nephropathie assoziierte dns | |
| SE0202959D0 (sv) | Peptide-Base passive immunization therapy for treatment of atherosclerosis | |
| WO2001079434A3 (en) | A novel polypeptide, a human signal peptidase 10 and the polynucleotide encoding the polypeptide | |
| WO2001075021A3 (fr) | Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide | |
| WO2001075010A3 (fr) | Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide | |
| WO2001079431A3 (fr) | Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1270595 Country of ref document: EP |
|
| EEFA | Change of the company name |